PRMT5(プロテインアルギニンメチルトランスフェラーゼ5)は、細胞内で様々な機能を持つ重要な酵素です。PRMT5は通常、ヒストンタンパク質の対称的および非対称的なジメチル化を触媒し、翻訳後修飾において重要な役割を果たします。しかし、過去20年間に実施された調査研究により、その調節不全がさまざまな疾患プロセスを促進し、魅力的な治療標的になることが明らかになりました。PRMT5標的療法市場はまだ初期段階にあり、有望な候補薬の中止による挫折がありますが、現在の市場環境は、PRMT5標的療法が幅広い疾患のさまざまな治療レジメンの不可欠な要素になる可能性がある未来を示しています。
目次
1. Introduction to PRMT5 Targeted Therapy
1.1 Overview
1.2 History and Evolution of PRMT5 Targeted Therapy
2. PRMT5 Targeted Therapy Approaches
2.1 Small Molecule Inhibitors
2.2 Protein Degraders
2.3 Small Molecule Activators
3. Role of PRMT5 Targeted Therapies by Indication
3.1 Cancers
3.1.1 Solid Cancers
3.1.2 Hematological Cancers
3.2 Autoimmune and Inflammatory Diseases
3.3 Cardiovascular Diseases
3.4 Microbial Infections
4. Global PRMT5 Targeted Therapies Clinical Trials Overview
4.1 By Company
4.2 By Indication
4.3 By Location
4.4 By Patient Segment
4.5 By Phase
5. Global PRMT5 Targeted Therapies Clinical Trials By Company, Indication and Phas
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II
6. PRMT5 Targeted Therapies Research and Market Trends by Region
6.1 US
6.2 UK
6.3 EU
6.4 China
6.5 Canada
7. PRMT5 Targeted Therapies Market Trends and Clinical Trials Outlook
7.1 Current Market Trends, Developments and Clinical Trials Assessment
7.2 Future Commercialization Opportunity
8. PRMT5 Targeted Therapies Market Dynamics
8.1 Drivers and Opportunities
8.2 Challenges and Restraints
9. Competitive Landscape
9.1 Abbisko Therapeutics
9.2 Agios Pharmaceuticals
9.3 Amgen
9.4 AstraZeneca
9.5 Aurigene Oncology
9.6 CytosinLab Therapeutics
9.7 Epizyme (Ipsen)
9.8 IngenOx Therapeutics
9.9 Johnson and Johnson
9.10 Jubilant Therapeutics
9.11 Mirati Therapeutics
9.12 Ryvu Therapeutics
9.13 Schrodinger
9.14 Simcere Pharmaceutical Group
9.15 SK Life Science
9.16 Tango Therapeutics
List of Figures & Tables
Figure 1-1: PRMT5 - Normal Functions
Figure 1-2: PRMT5 - Oncogenic Functions
Figure 1-3: PRMT5 - Important Milestones in Development
Figure 2-1: PRMT5 - Binding Sites for Small Molecule Inhibitors
Figure 2-2: PROTACs - Mechanism of Action
Figure 2-3: PROTACs - Advantages
Figure 3-1: PRMT5 - Roles in Solid Cancers
Figure 3-2: PRMT5 - Roles in Hematological Cancers
Figure 3-3: PRMT5 - Roles in Diabetes
Figure 3-4: PRMT5 - Roles in Microbial Infections
Figure 4-1: Global - PRMT5 Targeted Therapies Clinical Trials By Company
(Number), 2024
Figure 4-2: Global - PRMT5 Targeted Therapies Clinical Trials By Indication
(Number), 2024
Figure 4-3: Global - PRMT5 Targeted Therapies Clinical Trials By Location (Number),
2024
Figure 4-4: Global - PRMT5 Targeted Therapies Clinical Trials By Patient Segment
(Number), 2024
Figure 4-5: Global - PRMT5 Targeted Therapies Clinical Trials By Phase (Number),
2024
Figure 6-1: NCT05094336 Phase 1/2 Study - Initiation and Completion Year
Figure 6-2: NCT05528055 Phase 1 Study - Initiation and Completion Year
Figure 8 1: PRMT5 Targeted Therapies Market - Drivers and Opportunities
Figure 8 2: PRMT5 Targeted Therapies Market - Challenges and Restraints
List of Tables
Table 6-1: US - Ongoing Studies for PRMT5 Inhibitors
Table 6-2: UK - Ongoing Studies for PRMT5 Inhibitors
Table 6-3: EU - Ongoing Studies for PRMT5 Inhibitors
Table 6-4: China - Ongoing Studies for PRMT5 Inhibitors
Table 6-5: Canada - Ongoing Studies For PRMT5 Inhibitors
